Twist Bioscience CEO Emily Leproust sells $919,373 in stock

Emily M. Leproust, Chief Executive Officer and a Director of Twist Bioscience Corp (TWST), sold 4,548 shares of the company’s common stock on October 5, 2026, according to a recent SEC Form 4 filing. The transactions totaled $919,373 and were executed at prices ranging from $200.4379 to $207.4556 per share.

The sale was conducted pursuant to a Rule 10b5-1 trading plan, which Ms. Leproust adopted on June 15, 2026. Notably, the stock has declined significantly since the transaction, currently trading at $159.78, down 15% over the past week despite posting a remarkable 412% return over the last year.

Following these transactions, Ms. Leproust directly holds 562,760 shares of Twist Bioscience common stock. The filing also noted her beneficial ownership of employee stock options, including 131,290 shares with an exercise price of $23.33 and 64,950 shares with an exercise price of $67.85. The latter vested on December 19, 2022, after performance criteria were met.According to InvestingPro analysis, the stock currently appears overvalued based on its Fair Value assessment. Investors seeking deeper insights can access a comprehensive Pro Research Report on TWST, one of 1,400+ available reports transforming complex data into actionable intelligence.

In other recent news, Twist Bioscience has been involved in several notable developments. The company announced an agreement with Eli Lilly’s TuneLab, where Twist will provide antibody characterization data services, enhancing its collaboration in AI/ML drug discovery. Additionally, Twist Bioscience filed a prospectus supplement to register the resale of shares to Invenra Inc., linked to a Stock Purchase Agreement. Analyst activity around Twist Bioscience has been varied, with Jefferies initiating coverage with a Hold rating and a $150.00 price target. Meanwhile, BWS Financial has taken a more cautious stance, issuing a sell rating and a $45.00 price target due to perceived premium valuation compared to peers. Guggenheim, however, remains optimistic, reiterating a Buy rating with a $107.00 price target, emphasizing potential in AI drug discovery. These developments reflect diverse perspectives on Twist Bioscience’s market position and future prospects.